Sino Biopharmaceutical Ltd
HKEX:1177

Watchlist Manager
Sino Biopharmaceutical Ltd Logo
Sino Biopharmaceutical Ltd
HKEX:1177
Watchlist
Price: 3.22 HKD 0.31% Market Closed
Market Cap: 60.5B HKD
Have any thoughts about
Sino Biopharmaceutical Ltd?
Write Note

Operating Margin
Sino Biopharmaceutical Ltd

23.1%
Current
21%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
23.1%
=
Operating Profit
6.2B
/
Revenue
26.8B

Operating Margin Across Competitors

Country HK
Market Cap 59B HKD
Operating Margin
23%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 743.6B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.7T DKK
Operating Margin
44%
Country US
Market Cap 346B USD
Operating Margin
28%
Country US
Market Cap 248.8B USD
Operating Margin
34%
Country CH
Market Cap 199.5B CHF
Operating Margin
32%
Country UK
Market Cap 161.6B GBP
Operating Margin
21%
Country CH
Market Cap 171.3B CHF
Operating Margin
31%
Country US
Market Cap 149.2B USD
Operating Margin
22%
No Stocks Found

Sino Biopharmaceutical Ltd
Glance View

Market Cap
59B HKD
Industry
Pharmaceuticals

Sino Biopharmaceutical Ltd. emerged as a key player in the Chinese healthcare landscape, rooted in the rich cultural hubs of Beijing and Hong Kong. As the tapestry of modern medicine interweaves ever more tightly with advanced research, Sino Biopharmaceutical positions itself at this critical juncture. The company delves extensively into the discovery, development, manufacturing, and commercialization of a broad spectrum of pharmaceuticals. With a keen focus on therapeutic areas like oncology, hepatitis, and cardio-cerebral diseases, they forge pathways for innovative treatments that resonate widely in the fast-developing Chinese medical market. Driven by its Research and Development prowess, Sino Biopharmaceutical garners considerable strength from its portfolio of proprietary drugs, underscoring a growth strategy deeply rooted in innovation and quality. The financial blueprint of Sino Biopharmaceutical delicately balances its expansive production capacities with a robust distribution network, encapsulating an effective end-to-end operation from lab to patient. Revenue streams are predominantly anchored in its extensive sales of prescription drugs, particularly high-margin specialty pharmaceuticals that address critical and chronic health conditions. Leveraging strategic alliances and collaborations with both domestic and international partners, the company enhances its technological capabilities and global reach. Moreover, its enduring commitment to sustainable practices and compliance wields influence over its operational efficiencies, allowing Sino Biopharmaceutical to navigate and capitalize on regulatory environments while meeting the burgeoning healthcare needs across its business region.

Intrinsic Value
3.97 HKD
Undervaluation 19%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
23.1%
=
Operating Profit
6.2B
/
Revenue
26.8B
What is the Operating Margin of Sino Biopharmaceutical Ltd?

Based on Sino Biopharmaceutical Ltd's most recent financial statements, the company has Operating Margin of 23.1%.